|
|
|
|
| Culture of human pluripotent stem cells using completely defined conditions
on a recombinant E-cadherin substratum
Culture of human pluripotent stem cells using completely defined conditions on a recombinant
E-cadherin substratum
http://7thspace.com/headlines/346526/culture_of_human_pluripotent_stem_cells_using_completely_defined_conditions_on_a_recombinant_e_cadherin_substratum.html
To maintain pluripotency of human embryonic stem (huES) cells in feeder-free culture, it has
been necessary to provide a Matrigel substratum, which is a complex of poorly defined
extracellular matrices and growth factors derived from mouse Engelbreth-Holm-Swarm sarcoma
cells. Culture of stem cells under poorly defined conditions can inhibit the effectiveness of
maintaining cells in a pluripotent state and reduce reproducibility of differentiation
protocols.
Moreover recent batches of Matrigel have been found to be contaminated with the single stranded
RNA virus, Lactate Dehydrogenase Elevating Virus (LDEV), raising concerns regarding the safety
of using stem cells that have been cultured on Matrigel in a therapeutic setting. To circumvent
such concerns, we attempted to identify a recombinant matrix that could be used as an
alternative to Matrigel for the culture of human pluripotent stem cells.
huES and human induced pluripotent stem (hiPS) cells were grown on plates coated with a fusion
protein consisting ofE-cadherin and the IgG Fc domain using mTeSR1 medium.
Results: Cells grown under these conditions maintained similar morphology and growth rate to
those grown on Matrigel and retained all pluripotent stem cell features, including an ability to
differentiate into multiple cell lineages in teratoma assays. We, therefore, present a culture
system that maintains the pluripotency of huES and hiPS cells under completely defined
conditions.
Conclusions: We propose that this system should facilitate growth of stem cells using good
manufacturing practices (GMP), which will be necessary for the clinical use of pluripotent stem
cells and their derivatives.
June 3, 2010 (7thSpace Interactive)
|
|
|
Licenţa de Ministerul Sănătăţii din Ucraina seria AG № 570573 din 10.03.2011
Licenta de Ministerul Sănătăţii din Ucraina seria AB № 511037 din 03.12.2009 ©
Institutul de terapie celulară 2004-2011
|